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Background/Significance 
• Continued smoking among patients with existing 
cardiac disorders or prior cardiac events is associated 
with increased risk for subsequent fatal cardiac events 
(Gerber, Rosen, Goldbourt, Benyamini, & Drory, 2009; Kinjo et al., 2005).   
 
• Up to 62% of individuals with cardiac conditions 
continue to smoke, even after experiencing life-
threatening events (Colivicchi et al., 2011; Rea et al., 2002). 
Smoking Cessation and Cardiology Patients  
• Smoking cessation interventions associated with reduced 
rates of premature death among cardiac patients (Van Berkel, 
Boersma, Roos-Hesselink, Erdman, & Simoons, 1999).  
 
• In a retrospective study of 3511 current smokers with acute 
myocardial infarction (AMI) attending hospitals in Ontario, 
only 52% were offered smoking cessation counseling. The 
group of patients receiving smoking cessation counseling 
was significantly less likely to experience mortality in the 
year following hospitalization compared to those not 
receiving counseling. (Van Spall et al., 2007)  
 
Smoking cessation and cardiology patients 
• A randomized controlled trial of a an intensive smoking 
cessation programme compared to usual care among 
cardiac patients found significantly higher 2-year continuous 
abstinence rates in the intensive smoking cessation group 
versus the usual care group (33% vs. 9%). (Mohiuddin et al., 2007).  
 
•  Moreover mortality rate (all causes) was 2.8% in the 
intensive smoking cessation group versus 12.0% in the 
usual care group over the 2-year follow up period (Mohiuddin et 
al., 2007).  
 
• But few studies in Canada have examined outcomes of 
delivering smoking cessation among cardiology patients.  
 
 
Purpose 
• Examine smoking cessation and reduction 
outcomes of an intensive tobacco treatment 
programme in cardiology services 
 
• Examine predictors of smoking cessation  
Intervention 
• The SCC programme takes a longitudinal approach to 
tobacco treatment, a process which has no set end-point. 
 
• Pharmacotherapy. A recommendation for the use of 
pharmacotherapy is provided to all participants. Options 
include NRT (i.e., nicotine gum, patch, lozenge, inhaler or 
oral spray), varenicline or buproprion SR. Combinations of 
these products are frequently utilized. A medication 
protocol was established for the SCC programme based on 
existing treatment algorithms for the use of 
pharmacotherapy in clinics and outpatient settings (Bader, 
McDonald, & Selby, 2009).  
Participants and Sample 
N = 145 
Attended initial clinic visit between 
 (September 16th, 2010 to May 24th, 2012 
n = 28 
Not engaged participants 
 (i.e., did not return for a follow-
up visit beyond initial 
assessment) 
117 
Intent to treat 
n = 93 
Cardiology services 
(referred by cardiology providers, 
cardiac and heart fibrillation clinics, 
and catheterization/  stress/ 
echocardiogram labs) 
n = 12  
Other sources  
 
(referred by other hospital 
services [i.e., men’s health, 
urology, neurology, arthritis 
clinic] and general practice 
providers, and self-referrals) 
n = 12 
Respirology Services 
 
(referred by respirology 
providers, chronic obstructive 
pulmonary disease transition, 
and lung clinics) 
33.6%
66.4%
Gender
Female Male
34.2%
20.5%
20.5%
24.8%
History of a Psychiatric or 
Substance use disorder?
Neither Psychiatric only
Substance use only Both
Sample Characteristics (n = 117) 
Smoking Cessation Stage of Change 
26.5%
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Income Sources 
Sample Characteristics (contd.) 
Mean Stand. Dev. 
Age of participant (years) 58.5 10.5 
Age at smoking initiation (years) 16.4 4.4 
Importance of quitting (scale of 0 ‘low’ to 10 ‘high’) 8.6 2.0 
Confidence in quitting (scale of 0 ‘low’ to 10 ‘high’) 6.3 2.6 
Number of cigarettes smoked per day 15.9 8.0 
Fagerstrom Test for Nicotine Dependence  
(scale of 0 ‘low’ to 10 ‘high’) 
4.2 2.4 
Number of medical co-morbidities  2.8 1.3 
CO level at baseline (ppm) 15.8 9.6 
Average number of visits to the programme 5.0 3.3 
Length of time in the programme (in weeks) 19.1 16.2 
Smoking Cessation outcomes by referral source 
36.6 33.3
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Note. No significant difference in cessation outcomes by referral source (χ2=0.64, p = .785) 
Smoking reduction outcomes by referral source 
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Note. No significant difference in cessation outcomes by referral source (χ2=0.49, p = .783) 
Smoking cessation by time engaged in the 
programme (n = 117) 
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Note. Significant linear trend  with greater likelihood of cessation with longer 
engagement in programme  (χ2 = 5.2 [df = 1], p = .023) 
Duration of abstinence among those who 
achieved cessation (n = 41) 
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Multivariate associationsa of smoking cessation during 
analysis period (n = 117) 
Predictors Odds Ratio 95%CI 
Gender 
    Male (referent) 
    Female 
 
1.0 
.3* 
 
- 
.1-1.0 
Stage of Change 
     Precontemplative/Contemplative (referent) 
     Preparation/Action 
 
1.0 
3.3 
 
- 
1.0-11.3 
     Confidence in quitting 
1.1 .9-1.3 
     FTND at baseline 
.9 .7-1.1 
     Expired CO level at baseline 
.9 .9-1.0 
     Length of time in the programme (in weeks) 
1.0** 1.0-1.1 
* = p <.05, ** = p <.001, *** = p <.001 
a Hosmer and Lemeshow goodness-of-fit test χ2 = 3.2 [df = 8], p = .923 
Summary of Key Findings 
• Smoking abstinence/cessation  outcomes: 
– Cessation among those engaged in the programme: 35.5%(41/117)  
– Reduction among those unable to achieve abstinence: 42.1% (32/76)  
 
• Significant predictors of abstinence : 
– Being male.   
– Attending the SCC program for a longer duration. 
 
 • Limitations: 
– Retrospective analysis design 
– Use of 7-day point prevalence abstinence as measure of smoking 
cessation outcome  
– Analysis of existing data (missing variables such as education level) 
– Relatively low sample size (n = 117)  
– Patients motivated to quit smoking, self-selection bias 
 
 
 
Conclusions/Implications 
 
 
• Need for tobacco treatment programmes within hospital 
settings. 
 
 
• Consideration of a longitudinal approach to tobacco 
treatment 
 
 
 
 
 
